Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience

ABSTRACT Background Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody–drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory t...

Descrición completa

Detalles Bibliográficos

Principais autores:	Mimma Rizzo, Franco Morelli, Yüksel Ürün, Sebastiano Buti, Se Hoon Park, Maria T. Bourlon, Enrique Grande, Francesco Massari, Johannes Landmesser, Alexandr Poprach, Hideki Takeshita, Giandomenico Roviello, Zin W. Myint, Lazar Popovic, Andrey Soares, Halima Abahssain, Patrizia Giannatempo, Javier Molina‐Cerrillo, Lorena Incorvaia, Samer Salah, Annalisa Zeppellini, Fernando Sabino Marques Monteiro, Camillo Porta, Shilpa Gupta, Matteo Santoni
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-02-01
Series:	Cancer Medicine
Assuntos:	ARON‐2 study chemotherapy enfortumab vedotin NCT05290038 pembrolizumab real‐world data
Acceso en liña:	https://doi.org/10.1002/cam4.70479
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!